MindMaze is a Swiss neurotechnology company founded in 2012 that specializes in digital therapeutics and brain-computer interface (BCI) technology for neurorehabilitation. The company develops FDA-cleared and CE-marked software medical devices that use AI and BCI to help patients recover from neurological injuries including stroke, traumatic brain injury, and neurodegenerative diseases[1].
MindMaze's core technology platform combines:
The company's flagship products include:
MindMaze's digital therapeutics are primarily used for post-stroke motor recovery. The VR-based platform provides engaging rehabilitation exercises while AI algorithms adapt difficulty based on patient performance[3].
For conditions like Parkinson's Disease and Alzheimer's Disease, MindMaze offers:
The BCI component allows patients with complete paralysis to communicate through neural signal detection, providing a crucial communication channel for ALS patients[4].
MindMaze has raised over $105M in funding, with key investors including:
The company has partnerships with major rehabilitation hospitals and research institutions globally.
MindMaze's BCI technology interfaces with several key neurodegenerative disease mechanisms:
Motor Cortex — Primary target for neural signal recording
Synaptic Transmission — Neural signal decoding
Neuroplasticity — Cortical adaptation to neural interfaces
BDNF Signaling — Long-term neural integration
Cortical Oscillations — Neural decoding
Alzheimer's Disease — Cognitive monitoring
Parkinson's Disease — Motor symptom management
Amyotrophic Lateral Sclerosis (ALS) — Communication interfaces
Stuckelberger S, et al. MindMaze: A VR/BCI Platform for Stroke Rehabilitation. Frontiers in Neuroscience. 2018. ↩︎
FDA. 510(k) Summary: MindMotion Pro. 2024. ↩︎
Perez-Marcos D, et al. Virtual reality rehabilitation for stroke: a systematic review. Topics in Stroke Rehabilitation. 2019. ↩︎
Blank A, et al. Brain-computer interface for locked-in communication. Brain-Computer Interfaces. 2020. ↩︎